Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sudarshan Hebbar

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Current Opinion in Immunology|April 23, 2026
CRAC channels as targets for immunotherapyKenneth Stauderman, Sudarshan Hebbar, Stefan Feske
Clinical Transplantation|April 9, 2008
Adverse drug reaction driven immunosuppressive drug manipulations: a single-center comparison of enteric-coated mycophenolate sodium vs. mycophenolate mofetilKaren L Hardinger, Sudarshan Hebbar, Terry Bloomer, et al.
Nephron|December 17, 2025
Bench to Bedside: Translating Discoveries to Clinical Care in Kidney DiseaseKatharine Epler, Dana Y Fuhrman, Sudarshan Hebbar, et al.
Pancreas|May 3, 2021
Auxora for the Treatment of Patients With Acute Pancreatitis and Accompanying Systemic Inflammatory Response Syndrome: Clinical Development of a Calcium Release-Activated Calcium Channel InhibitorCharles Bruen, Joseph Miller, John Wilburn, et al.
Journal of Neurotrauma|October 24, 2018
Microglial Calcium Release-Activated Calcium Channel Inhibition Improves Outcome from Experimental Traumatic Brain Injury and Microglia-Induced Neuronal DeathAtsushi Mizuma, Jong Youl Kim, Rachid Kacimi, et al.
Journal of the American Society of Nephrology : JASN|August 4, 2012
Bardoxolone methyl decreases megalin and activates nrf2 in the kidneyScott A Reisman, Glenn M Chertow, Sudarshan Hebbar, et al.
Critical Care (London, England)|August 16, 2020
Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trialJoseph Miller, Charles Bruen, Michael Schnaus, et al.
American Journal of Nephrology|June 9, 2025
Inhibition of Calcium Release-Activated Calcium Channels to Treat Acute Kidney Injury: Design and Rationale of the KOURAGE Study a Randomized TrialLakhmir S Chawla, Patrick T Murray, Stuart L Goldstein, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 7, 2004
Medication prescribing patterns in ambulatory haemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis providerHarold J Manley, Cory G Garvin, Debra K Drayer, et al.
Critical Care (London, England)|April 9, 2022
Auxora vs. placebo for the treatment of patients with severe COVID-19 pneumonia: a randomized-controlled clinical trialCharles Bruen, Mukhtar Al-Saadi, Edward A Michelson, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Current Opinion in Immunology|April 23, 2026
CRAC channels as targets for immunotherapyKenneth Stauderman, Sudarshan Hebbar, Stefan Feske
Clinical Transplantation|April 9, 2008
Adverse drug reaction driven immunosuppressive drug manipulations: a single-center comparison of enteric-coated mycophenolate sodium vs. mycophenolate mofetilKaren L Hardinger, Sudarshan Hebbar, Terry Bloomer, et al.
Nephron|December 17, 2025
Bench to Bedside: Translating Discoveries to Clinical Care in Kidney DiseaseKatharine Epler, Dana Y Fuhrman, Sudarshan Hebbar, et al.
Pancreas|May 3, 2021
Auxora for the Treatment of Patients With Acute Pancreatitis and Accompanying Systemic Inflammatory Response Syndrome: Clinical Development of a Calcium Release-Activated Calcium Channel InhibitorCharles Bruen, Joseph Miller, John Wilburn, et al.
Journal of Neurotrauma|October 24, 2018
Microglial Calcium Release-Activated Calcium Channel Inhibition Improves Outcome from Experimental Traumatic Brain Injury and Microglia-Induced Neuronal DeathAtsushi Mizuma, Jong Youl Kim, Rachid Kacimi, et al.
Journal of the American Society of Nephrology : JASN|August 4, 2012
Bardoxolone methyl decreases megalin and activates nrf2 in the kidneyScott A Reisman, Glenn M Chertow, Sudarshan Hebbar, et al.
Critical Care (London, England)|August 16, 2020
Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trialJoseph Miller, Charles Bruen, Michael Schnaus, et al.
American Journal of Nephrology|June 9, 2025
Inhibition of Calcium Release-Activated Calcium Channels to Treat Acute Kidney Injury: Design and Rationale of the KOURAGE Study a Randomized TrialLakhmir S Chawla, Patrick T Murray, Stuart L Goldstein, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 7, 2004
Medication prescribing patterns in ambulatory haemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis providerHarold J Manley, Cory G Garvin, Debra K Drayer, et al.
Critical Care (London, England)|April 9, 2022
Auxora vs. placebo for the treatment of patients with severe COVID-19 pneumonia: a randomized-controlled clinical trialCharles Bruen, Mukhtar Al-Saadi, Edward A Michelson, et al.
Pageof 2